Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.
Ranzenigo M, Gianotti N, Galli L, Poli A, Mastrangelo A, Bruzzesi E, Chiurlo M, Nozza S, Bossolasco S, Spagnuolo V, Mancusi D, Termini R, Carini E, Lazzarin A, Castagna A. Ranzenigo M, et al. Among authors: termini r. Drug Des Devel Ther. 2022 Jun 27;16:1975-1982. doi: 10.2147/DDDT.S358976. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35783200 Free PMC article.
T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor in HIV-infected late presenters: results from a retrospective, ex vivo study.
Tincati C, Savoldi A, Cannizzo ES, Bellistrì GM, Termini R, Garau M, Mancusi D, d'Arminio Monforte A, Marchetti G. Tincati C, et al. Among authors: termini r. Antivir Ther. 2016;21(2):133-42. doi: 10.3851/IMP2990. Epub 2015 Sep 10. Antivir Ther. 2016. PMID: 26355423
Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.
Antinori A, Meraviglia P, Monforte Ad, Castagna A, Mussini C, Bini T, Gianotti N, Rusconi S, Colella E, Airoldi G, Mancusi D, Termini R. Antinori A, et al. Among authors: termini r. Drug Des Devel Ther. 2016 May 6;10:1589-603. doi: 10.2147/DDDT.S104875. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27226708 Free PMC article.
Cardiovascular disease in women with HIV-1 infection.
Volpe M, Uglietti A, Castagna A, Mussini C, Marchetti G, Bellagamba R, Bini T, Mancusi D, Termini R. Volpe M, et al. Among authors: termini r. Int J Cardiol. 2017 Aug 15;241:50-56. doi: 10.1016/j.ijcard.2017.02.117. Epub 2017 Feb 27. Int J Cardiol. 2017. PMID: 28285796 Free article. Review.
Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study.
Gori A, Antinori A, Vergori A, Cossu MV, Menzaghi B, Sterrantino G, Rusconi S, Cattelan AM, Castelli F, Gianotti N, Orofino G, Ripamonti D, Savinelli S, Manzillo E, Santantonio TA, Celesia BM, Cauda R, Maserati R, d'Arminio Monforte A, Stingone C, Bonora S, Uglietti A, Termini R, Rucci F, Mancusi D. Gori A, et al. Among authors: termini r. J Acquir Immune Defic Syndr. 2020 Jul 1;84(3):290-294. doi: 10.1097/QAI.0000000000002331. J Acquir Immune Defic Syndr. 2020. PMID: 32101882 Free PMC article.
50 results